Costello Medical ISPOR Presentations

ISPOR 19th Annual European Congress, November 2016, Vienna, Austria

**IP7** How Should Biosimilars be Valued and Should They Undergo Health Technology Assessment?  
Kusel J, Psachoulia E, McKenna F, Walker A

**IP21** Is Off-Label Drug Use Enhancing or Limiting Access for Patients with Rare Diseases?  
Griffiths A, Scannell J, Timmis O, Pinilla-Dominguez P

**PRM128** Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: An Exploratory Evaluation Using Advanced Hierarchical Network Meta-Analysis Techniques  

**PRM210** Adapting to the Challenge: How are Innovative Study Designs Being Used in Rare Diseases?  
Berry L, Eddowes L

**PIN70** Health State Utility Values Measured Using the EuroQol 5-Dimensions Questionnaire in Adults with Chronic Hepatitis C: A Systematic Literature Review  
Buchanan-Hughes A, Hanman K, Langford B, Eddowes L

**PHP6** Patient Group Submissions in Health Technology Assessment in Scotland: Prevalence and Impact  
Hamilton K, Hanman K, Griffiths M

**PHP94** Do Scottish Formulary Decisions Match Recommendations Made by the SMC?  
Beale R, Kusel J

**PCV16** Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: A Systematic Literature Review  

**PSY156** A Value for Money Threshold for New Technologies for Very Rare Conditions: Does the NICE Highly Specialised Technology Committee Employ One?  
Kusel J, Griffiths A, Spoors J

**PCN236** Innovative Therapies for the Treatment of Cancer: An Overview of Late-Phase Clinical Development  
Resemann H, Chainani N, Morten P, Griffiths M

**PCN294** Reconsidering Drugs Funded via the Cancer Drugs Fund in England: What’s New This Time?  
Morten P, Lin Z, Kusel J

**PMD23** Cost of Ebola Virus Disease Diagnosis Using Rapid Point-of-Care Diagnostics in Sierra Leone  
Evans J, Hearmon N, Beale R, Marsh W

**PMD59** Investigating the Cost-Effectiveness of Genetic Counselling for Couples at Known Risk of Having Children with Tay-Sachs Disease: A Two-Generation Model  
Ghosh W, Griffiths M, Griffiths A
ISPOR 7th Asia-Pacific Conference, September 2016, Singapore

IP3 Joint HTA: The Next Step for the ASEAN Economic Community?
Chen G, Ngorsurachet S, Redekop K

IP15 Should Productivity Losses due to Illness be Considered in Health Economic Evaluations?
Brooks-Rooney C, Redekop K, Wee HL, Milea D

PCV33 Measurement of Adherence to Anti-Hypertensive Drugs in Asia
Ma Q, Kao C, Miles G, Chen G

PCV54 Quantifying Informal versus Formal Care, and Financial Caregiver Burden, for Stroke Patients in Asia: A Structured Literature Review
Wayman S, Langford B, Buchanan-Hughes A, Chen G

PHP38 Universal Health Coverage in Countries across East and South East Asia – Associations between Health Expenditure and Service Provision
Evans J, Wickstead R, Hanman K, Steeves S

PIN15 Economic Burden of Antibiotic-resistant Nosocomial Gram-Negative Bacteraemia in Singapore Hospitals
Chen G, Lim S, Ma Q, Kao C, Ghosh W

PMH16 Estimating the Economic Impact due to Productivity Losses of Diabetes and Major Depressive Disorder in Singapore: Human Capital versus Friction Cost Approaches
Brooks-Rooney C, Griffiths M, Chen G

ISPOR 21st Annual International Meeting, May 2016, Washington DC, USA

PHP54 The Trade-Off Between QALY Maximisation and Social Values: A Systematic Review of Public Opinion Surveys
Buchanan-Hughes A, Kusel J

ISPOR 18th Annual European Congress, November 2015, Milan, Italy

PCN323 Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England?
Stewart G, Kusel J, Montgomery S

PUK15 Investigating the Cost-Effectiveness of Bacterial Whole-Genome Sequencing for Enabling Targeted Antibiotic Selection in Urinary Tract Infections
Buchanan-Hughes A, Griffiths A, Evans J, Slater D, Eddowes L

PDB116 The Role of Education in the Management of Type 1 Diabetes Mellitus in England
Toth C, Marsh W, Stewart G, Yang L, Bridges H, Kusel J

PRM237 Using Incentives to Improve Health-Related Behaviours: A Review of Incentive-Based Trials
Bunting C, Lim S, Morten P

PRM267 Development of a PRECIS-2 Scoring Grid: How Pragmatic are Pragmatic Trials of Surgical and Pharmaceutical Interventions?
Chen G, Ma Q, Yang L, Ghosh W, Kusel J

PRM55 Hunting for Randomised Controlled Trials (RCTs): A Comparison of Search Filters Designed to Identify RCTs
Steeves S, Buchanan-Hughes A, Evans J, Leonard S
ISPOR 5th Latin America Conference, September 2015, Santiago, Chile

IP2 Disinvestment in Latin America: What are the Experiences, Challenges and Proposals for its Successful Implementation?
Agirrezabal I, Rodríguez A, Esandi ME, Gutiérrez-Ibarluzea I

PP4 An Undeveloped Picture: The Availability of Utility Valuations in Latin America. How Will They Affect QALYs?
Montgomery S, Stewart G, Kusel J

PHP23 Pharmaceutical Cost-Containment Strategies – Opinions of the Pharmaceutical Industry and HTA Bodies in Latin America
Beale R, Stewart G, Agirrezabal I, Kusel J

PHP24 Immunisation in Latin America: Factors Preventing Uptake of Cost-Effective Vaccines
Burgon J, Bunting C, Eddowes LA, Wilson T

PHP38 Considerations for the Adoption of the WHO-CHOICE Cost-Effectiveness Threshold in Latin America
Griffiths M, Latchford J, Stewart G, Kusel J

PHP40 Clinical Trial Trends in Latin America: Communicable Versus Non-Communicable Disease
Anderson R, Wilson T

PHP54 Disinvestment Initiatives in Latin America: A Systematic Literature Review
Agirrezabal I, Latchford J, Gutierrez-Ibarluzea I

PRM9 A Systematic Review of Economic Evaluations in Latin America: Assessing the Factors That Affect Adaptation and Transferability of Results
Stewart G, Slater D, Maruszczak M

ISPOR 20th Annual International Meeting, May 2015, Philadelphia, USA

PMD34 A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Detecting and Monitoring Outbreaks of MRSA
Agirrezabal I, Buchanan-Hughes A, Eddowes L, Luhashi L, Sagoo GS, Török ME

PMD37 A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Monitoring Outbreaks of Clostridium difficile
Buchanan-Hughes A, Agirrezabal I, Eddowes L, Luhashi L, Török ME, Sagoo GS

PRM28 Implication of the Inter-relatedness of the Proportional and Absolute QALY Shortfall Measurements for Disease Burden
Kusel J, Beale R, Maruszczak M

PHP107 The WHO-Choice Cost-effectiveness Threshold: A Country-level Analysis of Changes Over Time
Griffiths M, Maruszczak M, Kusel J

ISPOR 17th Annual European Congress, November 2014, Amsterdam, The Netherlands

W5 Value-based Assessment for NICE: How to Do the Calculations
Kusel J, Boysen M, Hatswell AJ, Shah K

HS3 Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals
Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J

QA1 Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications
Montgomery S, Hassan M, Kusel J

NI2 Predicting the Impact of Value-based Assessment on Future NICE Appraisals
Beale RC, Maruszczak M, Kusel J

PGI17 A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective
Miles G, Leonard SA, Ghosh N, Premchand P
ISPOR 16th Annual European Congress, November 2013, Dublin, Ireland

IP13 Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?  
Kusel J, Walker W, Spackman E, Andersson C

PCN207 Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data  
Wilson T, Hamerslag L, Kusel J

PHP152 The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval  
Burgon J, Hamerslag L

PHP166 How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?  
Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J

PMH68 How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK  
Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J

PMS27 Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs  
Miles G, Bell J, Wilson T, Hamerslag L, Kusel J

ISPOR 18th Annual International Meeting, May 2013, New Orleans, USA

PSY89 Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?  
Hay J, Barber R, Kusel J, Wilson T

PMS48 Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?  
Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PHP104 Assessing the Implementation of NICE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice  

ISPOR 15th Annual European Congress, November 2012, Berlin, Germany

NI2 The Use of Off-Label Comparators in NICE Appraisals – An Indirect Endorsement?  
Kusel J, Wong GK, Hay JA, Pettit LJ

CA2 Applying a Value-Based Price Across Different Disease Areas  
Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PCN144 Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NICE’s End-of-Life Therapies?  
Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L
ISPOR 5th Asia-Pacific Conference, September 2012, Taipei, Taiwan

HC4 Tapping into the Asian Pharmaceutical Market: Global Firms Go Local?

PHP82 The Characteristics of Clinical Trials in Asia
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

PRM11 The Use of Biomarkers in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

ISPOR 17th Annual International Meeting, June 2012, Washington DC, USA

PCN148 The Use of Personalised Medicine in Cancer Trials

PHP66 Assessing Agreement Between Patient Access Schemes: Review of NICE and SMC Guidance
Timm B, Leonard S, Haynes S

PRM11 The Rise of Budget Impact Analyses – Another Hurdle in the Health Technology Approval Process?
Wong GKW, Hamer N, Wilson T, Costello S

ISPOR 14th Annual European Congress, November 2011, Madrid, Spain

Hamerslag L, Haynes S, Kusel J, Costello S

RS4 The Interim Cancer Drugs Fund – How To Not Spend £50 Million
Timm B, Brooks-Rooney C, Hamerslag L, Costello S

PHP123 To What Extent Does Advice From the SMC Agree with that Published by NICE?
Leonard SA, Brooks-Rooney C, Kusel J, Costello S

PHP145 The Burden of Evidence in the Pharmaceutical Appraisal Process

PHP152 The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study

PRM9 What Guidance is Available for Budget Impact Analysis?
Kusel J, Leonard S, Wilson T, Costello S

ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA

PRM3 The Burden of Caregiving: Assessing the Status of Current Clinical Research
Hamer N, Costello S, Hamerslag L, Haynes S, Roper S

PHP5 Incentive-based Interventions – Rewarding Patients for Good Behaviour
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP7 Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence Identified by NICE in the UK
Kusel J, Hamer N, Roper S, Hamerslag L, Costello S

PHP43 The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK

PHP89 The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions
Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

PMS69 The Use of Mixed Treatment Comparisons in NICE Technology Appraisals
NI4 Do Patient Access Schemes Result in an Acceptable Administrative Burden?
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP94 Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?

PHP98 Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals

ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA

PHP79 Innovative Pricing Agreements in UK NICE Submissions
Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N